MorphoSys Secures Full-Term of Strategic Alliance>
MorphoSys Secures Full-Term of Strategic Alliance
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announcedtoday that Novartis has committed to a ten-year term of the strategicalliance originally signed in December 2007. The decision was basedon the successful achievement by MorphoSys of certain predefinedimprovements in its proprietary technologies. The collaboration willnow run until 2017 and may be extended by Novartis for an additionaltwo years beyond that time under the same financial terms andconditions. The option for Novartis to terminate the alliance afterseven years is thereby removed."Today's news further increases the secured value for MorphoSys fromour largest therapeutic alliance to date. Our alliance with Novartisis developing well and we are therefore delighted to be able toexploit its full potential", commented Dr. Simon Moroney, ChiefExecutive Officer of MorphoSys AG. "The latest technologicaladvances in our core antibody platform contributed significantly toachieving this extension."In December 2007, MorphoSys and Novartis forged one of the industry'smost comprehensive strategic alliances in the discovery anddevelopment of biopharmaceuticals. Financial terms include committedpayments in excess of US$600 million over the ten-year lifetime ofthe agreement. Within the collaboration, two antibody programs arecurrently in clinical development.For further information please contact: Dr. Claudia Gutjahr-Löser,Head of Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-122, gutjahr-loeser(at)morphosys.com or Mario Brkulj, SeniorManager Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-454, brkulj(at)morphosys.comAbout MorphoSys:MorphoSys is a publicly traded biotechnology company focused on thegeneration of fully human antibodies as a means to discover anddevelop innovative antibody-based drugs against life-threateningdiseases. MorphoSys's goal is to establish HuCAL as the technology ofchoice for antibody generation in research, diagnostics andtherapeutic applications. The Company currently has therapeutic andresearch alliances with the majority of the world's largestpharmaceutical companies including Boehringer Ingelheim, CentocorOrtho Biotech Inc./Johnson & Johnson, Novartis, Pfizer and Roche.Within these partnerships, more than 50 therapeutic antibody programsare ongoing in which MorphoSys participates through exclusive licenseand milestones payments as well as royalties on any end products.Additionally, MorphoSys is active in the antibody research marketthrough its AbD Serotec business unit. The business unit hasoperations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.(Oxford). For further information please visithttp://www.morphosys.com/About the University of Melbourne / Melbourne Ventures:Melbourne Ventures Pty Ltd is the technology commercialisationcompany of the University of Melbourne, one of the top 40Universities in the world (Times Higher Education 2008). TheUniversity of Melbourne is renowned as Australia's leadingbiomedical enterprise, training more health professionals andattracting more nationally competitive grants for biomedical researchthan any other Australian university. A wholly owned subsidiary ofthe University, Melbourne Ventures provides commercialisation and IPmanagement expertise across the full breadth of faculties anddepartments, and is responsible for negotiating licences andinvestments for the transfer and commercialisation of Universitydeveloped technologies. For further information please visit ourwebsite at www.melbourneventures.com.HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registeredtrademarks of MorphoSys AGThis communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.http://hugin.info/130295/R/1327174/312592.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Ahlstrom to close down two nonwovens production lines in Italy>
">
" alt="Sparebanken Pluss renews and expands its contract with EDB>
">
Datum: 06.07.2009 - 01:30 Uhr
Sprache: Deutsch
News-ID 1002161
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Secures Full-Term of Strategic Alliance>
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
